MA40770B1 - Dérivés d'imidazoles pentacyclic fusionnés - Google Patents

Dérivés d'imidazoles pentacyclic fusionnés

Info

Publication number
MA40770B1
MA40770B1 MA40770A MA40770A MA40770B1 MA 40770 B1 MA40770 B1 MA 40770B1 MA 40770 A MA40770 A MA 40770A MA 40770 A MA40770 A MA 40770A MA 40770 B1 MA40770 B1 MA 40770B1
Authority
MA
Morocco
Prior art keywords
disorders
imidazole derivatives
fused pentacyclic
pentacyclic imidazole
relates
Prior art date
Application number
MA40770A
Other languages
English (en)
French (fr)
Other versions
MA40770A (fr
Inventor
Bruno Filoche-Romme
Haro Garcia Teresa De
Michael Deligny
Jag Paul Heer
Joanna Rachel Quincey
Mengyang Xuan
Zhaoning Zhu
Daniel Christopher Brookings
Mark Daniel Calmiano
Yves Evrard
Martin Clive Hutchings
James Andrew Johnson
Sophie Jadot
Jean Keyaerts
Coss Malcolm Mac
Matthew Duncan Selby
Michael Alan Shaw
Dominique Louis Léon Swinnen
Laurent Schio
Yann Foricher
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Publication of MA40770A publication Critical patent/MA40770A/fr
Publication of MA40770B1 publication Critical patent/MA40770B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA40770A 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés MA40770B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en) 2014-10-03 2015-10-02 Fused pentacyclic imidazole derivatives

Publications (2)

Publication Number Publication Date
MA40770A MA40770A (fr) 2021-03-24
MA40770B1 true MA40770B1 (fr) 2021-11-30

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40770A MA40770B1 (fr) 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés

Country Status (36)

Country Link
US (3) US10202405B2 (Direct)
EP (1) EP3201196B1 (Direct)
JP (1) JP6629847B2 (Direct)
KR (1) KR102442235B1 (Direct)
CN (1) CN107108672B (Direct)
AP (1) AP2017009809A0 (Direct)
AU (1) AU2015326798B2 (Direct)
BR (1) BR112017006669B1 (Direct)
CA (1) CA2962826C (Direct)
CL (1) CL2017000787A1 (Direct)
CO (1) CO2017003331A2 (Direct)
CR (1) CR20170167A (Direct)
DK (1) DK3201196T3 (Direct)
EA (1) EA032839B1 (Direct)
EC (1) ECSP17027306A (Direct)
ES (1) ES2885432T3 (Direct)
GT (1) GT201700044A (Direct)
HR (1) HRP20211605T1 (Direct)
HU (1) HUE056133T2 (Direct)
IL (1) IL251147B (Direct)
LT (1) LT3201196T (Direct)
MA (1) MA40770B1 (Direct)
MX (1) MX380578B (Direct)
MY (1) MY181019A (Direct)
PE (1) PE20170693A1 (Direct)
PH (1) PH12017500414B1 (Direct)
PL (1) PL3201196T3 (Direct)
RS (1) RS62423B1 (Direct)
SG (1) SG11201701796XA (Direct)
SI (1) SI3201196T1 (Direct)
TN (1) TN2017000083A1 (Direct)
TW (1) TWI719949B (Direct)
UA (1) UA120764C2 (Direct)
UY (1) UY36341A (Direct)
WO (1) WO2016050975A1 (Direct)
ZA (1) ZA201701946B (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701796XA (en) * 2014-10-03 2017-04-27 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN109195968B (zh) 2016-04-01 2022-02-11 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
US10669286B2 (en) 2016-04-01 2020-06-02 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
CN109219608B (zh) * 2016-04-01 2021-12-21 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
WO2017167995A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3596078B1 (en) 2017-03-15 2023-04-12 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
PE20200662A1 (es) * 2017-04-25 2020-06-11 Ucb Biopharma Sprl Derivados de imidazol, pentaciclico fusionado como moduladores de la actividad de tnf
EP3778593A4 (en) * 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
CN113227097B (zh) * 2018-10-24 2023-09-08 Ucb生物制药有限责任公司 作为tnf活性调节剂的稠合五环咪唑衍生物
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
AU2023385854A1 (en) * 2022-11-23 2025-06-12 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) * 2023-01-05 2024-07-11 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
CN121038791A (zh) 2023-04-26 2025-11-28 赛诺菲 使用肿瘤坏死因子α的小分子抑制剂治疗银屑病
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
WO2025038927A1 (en) * 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
WO2025137267A1 (en) * 2023-12-21 2025-06-26 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025212627A1 (en) * 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025244936A1 (en) * 2024-05-20 2025-11-27 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025255096A1 (en) * 2024-06-03 2025-12-11 Dana-Farber Cancer Institute, Inc. Cycloalkyl and heterocyclic modulators of tnf activity
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
CA2517281A1 (en) 2003-03-10 2004-10-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
JP5977344B2 (ja) 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
ES2675583T3 (es) * 2012-06-11 2018-07-11 Ucb Biopharma Sprl Bencimidazoles moduladores de TNF-alfa
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112016008276B1 (pt) 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
SG11201701796XA (en) * 2014-10-03 2017-04-27 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives

Also Published As

Publication number Publication date
EA032839B1 (ru) 2019-07-31
HUE056133T2 (hu) 2022-01-28
MX2017004201A (es) 2017-05-30
KR20170068503A (ko) 2017-06-19
TWI719949B (zh) 2021-03-01
TN2017000083A1 (en) 2018-07-04
IL251147A0 (en) 2017-04-30
US20210155637A1 (en) 2021-05-27
DK3201196T3 (da) 2021-09-06
PH12017500414B1 (en) 2021-09-10
EP3201196A1 (en) 2017-08-09
UY36341A (es) 2016-04-29
KR102442235B1 (ko) 2022-09-08
HRP20211605T1 (hr) 2022-01-21
LT3201196T (lt) 2021-09-27
SI3201196T1 (sl) 2021-12-31
CN107108672A (zh) 2017-08-29
EA201790734A1 (ru) 2017-09-29
WO2016050975A1 (en) 2016-04-07
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (en) 2021-07-28
MY181019A (en) 2020-12-16
BR112017006669A2 (pt) 2017-12-26
PL3201196T3 (pl) 2022-01-03
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
MX380578B (es) 2025-03-12
US20190367535A1 (en) 2019-12-05
CN107108672B (zh) 2019-11-08
MA40770A (fr) 2021-03-24
CR20170167A (es) 2017-08-10
US10202405B2 (en) 2019-02-12
CL2017000787A1 (es) 2017-11-24
NZ730256A (en) 2021-05-28
CA2962826C (en) 2023-08-08
AU2015326798B2 (en) 2020-01-02
TW201629067A (zh) 2016-08-16
PE20170693A1 (es) 2017-06-13
AP2017009809A0 (en) 2017-03-31
US20170305932A1 (en) 2017-10-26
SG11201701796XA (en) 2017-04-27
US10906919B2 (en) 2021-02-02
RS62423B1 (sr) 2021-10-29
JP2017531648A (ja) 2017-10-26
CA2962826A1 (en) 2016-04-07
GT201700044A (es) 2019-09-09
PH12017500414A1 (en) 2017-07-17
ECSP17027306A (es) 2017-05-31
AU2015326798A1 (en) 2017-04-06
JP6629847B2 (ja) 2020-01-15
BR112017006669B1 (pt) 2023-04-18
ES2885432T3 (es) 2021-12-13
IL251147B (en) 2020-05-31
ZA201701946B (en) 2018-07-25

Similar Documents

Publication Publication Date Title
MA40770B1 (fr) Dérivés d'imidazoles pentacyclic fusionnés
EA201992407A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
EA201792688A1 (ru) Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
EA201500133A1 (ru) Производные имидазопиразина в качестве модуляторов активности tnf
EA201892153A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
JOP20190041B1 (ar) مركبات وتركيبات كمثبطات لمستقبلات شبيهة بالتول إندوسومية
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
EA201892144A1 (ru) Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
EA201892142A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
EA201892149A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
EA201991294A1 (ru) Замещенное производное бензимидазола в качестве модулятора активности tnf
EP3445334A4 (en) NANOLIPOSOMES FOR THE DELAYED RELEASE OF TACROLIMUS FOR THE TREATMENT OF EYE DISEASES OF THE ANTERIOR SEGMENT
HK1240916A1 (en) Fused pentacyclic imidazole derivatives